Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations

Health Economics

Volumn 14, Issue 12, 2005, Pages 1217-1229

  Nixon, Richard M ^a   Thompson, Simon G ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cost effectiveness analysis; Covariate adjustment; Hierarchical models; Multicentre studies; Subgroups

Indexed keywords

ACCURACY; ARTICLE; BAYES THEOREM; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COVARIANCE; HUMAN; MEDICAL DECISION MAKING; METHODOLOGY; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZATION; STATISTICAL ANALYSIS;

BAYES THEOREM; CASE MANAGEMENT; COST-BENEFIT ANALYSIS; EMPLOYMENT; GREAT BRITAIN; HEALTH POLICY; HUMANS; MODELS, STATISTICAL; PSYCHIATRIC NURSING; RANDOMIZED CONTROLLED TRIALS;

EID: 29544447887     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.1008     Document Type: Article

References (45)

1. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. National Institute for Clinical Excellence: London, 2004.
2. Black N. Why we need observational studies to evaluate the effectiveness of health care. Br Med J 1996; 312: 1215-1218.
3. Senn SJ. Covariate imbalance and random allocation in clinical trials. Stat Med 1989; 8: 467-475.
4. Rothwell PM, Warlow CP. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. Lancet 1999; 353: 2105-2110.
5. O'Hagan A, Stevens JW. A framework for cost-effectiveness analysis from clinical trial data. Health Econ 2001; 10: 303-315.
6. Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998; 3: 233-245.
7. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990; 10: 212-214.
8. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18(suppl.): S68-S80.
9. Tambour M, Zethraeus N, Johannesson M. A note on confidence intervals in cost-effectiveness analysis. Int J Technol Assess Health Care 1998; 14: 467-471.
10. van Hout BA, Al MJ, Gordon GS, Rutten F. Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994; 3: 309-319.
11. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000; 9: 623-630.
12. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002; 11: 415-430.
13. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ 2004; 13: 461-475.
14. Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ 2005; 14: 471-485.
15. Burns T, Creed F, Fahy T, Thompson S, Tyrer P, White I. Intensive versus standard case management for severe psychotic illness: a randomised trial. UK 700 Group. Lancet 1999; 353: 2185-2189.
16. UK700 Group. cost-effectiveness of intensive v. standard case management for severe psychotic illness: UK700 case management trial. Br J Psychiatry 2000; 176: 537-543.
17. Nixon R, Thompson SG. Parametric modelling of cost data in medical studies. Stat Med 2004; 23: 1311-1331.
18. Willan AR, Lin DY. Incremental net benefit in randomised clinical trials. Stat Med 2001; 20: 1563-1574.
19. Sheather SJ, Jones MC. A reliable data-based bandwidth selection method for kernel density estimation. J R Stat Soc Ser B 1991; 53: 683-690.
20. Altman DG. Practical Statistics for Medical Research. Chapman and Hall: London, 1991.
21. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of health care interventions. Health Technol Assess 1999; 3: 1-134.
22. Duan N. Smearing estimate: a non-parametric retransformation method. J Am Stat Assoc 1983; 78: 605-610.
23. Byford S, Barber JA, Fiander M, Marshall S, Green J. Factors that influence the cost of caring for patients with severe psychotic illness: report from the UK700 trial. Br J Psychiatry 2001; 178: 441-447.
24. Russell LB, Sisk JE. Modeling age differences in cost-effectiveness analysis: a review of the literature. Int J Technol Assess Health Care 2000; 16: 1158-1167.
25. Coyle D, Buxton MJ, O'Brien BJ. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Econ 2003; 12: 421-427.
26. Tyrer P, Hassiotis A, Ukoumunne O, Piachaud J, Harvey K. Intensive case management for psycotic patients with borderline intelligence. Lancet 1999; 354: 999-1000.
27. Hassiotis A, Ukoumunne OC, Byford S, Tyrer P, Harvey K, Piachaud J, Gilvarry K, Fraser J. Intellectual functioning and outcome of patients with severe psychotic illness randomised to intensive case management. Report from the UK700 trial. Br J Psychiatry 2001; 178: 166-171.
28. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998; 7: 481-493.
29. Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Stat Med 2003; 22: 1955-1976.
30. Skene AM, Wakefield JC. Hierarchical models for multicentre binary response studies. Stat Med 1990; 9: 919-929.
31. Carlin JB. Meta-analysis for 2 × 2 tables: a Bayesian approach. Stat Med 1992; 11: 141-158.
32. Brown HK, Kempton RA. The application of REML in clinical trials. Stat Med 1994; 13: 1601-1617.
33. Grieve R, Nixon RM, Thompson SG, Normand C. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Econ 2005; 14: 185-196.
34. Pocock SJ. Clinical Trials: a Practical Approach. Wiley: Chichester, 1983.
35. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 461-494.
36. Deb P, Burgess JF. A quasi-experimental comparison of econometric models for health care expenditures. Hunter College Department of Economics Working Papers 2003; 212.
37. Barber JA, Thompson SG. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy 2004; 9: 197-204.
38. O'Hagan A, Stevens JW. Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality? Health Econ 2003; 12: 33-49.
39. Zhou XH. Inferences about population means of health care costs. Stat Methods Med Res 2002; 11: 327-339.
40. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355: 1064-1069.
41. Oxman AD, Guyatt GH. A consumers guide to subgroup analyses. Ann Intern Med 1992; 116: 78-84.
42. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 341-364.
43. Johnston K, Gray A, Moher M, Yudkin P, Wright L, Mant D. Reporting the cost-effectiveness of interventions with nonsignificant effect differences: example from a trial of secondary prevention of coronary heart disease. Int J Technol Assess Health Care 2003; 19: 476-489.
44. Willan AR, Chen EB, Cook RJ, Lin DY. Incremental net benefit in randomized clinical trials with quality-adjusted survival. Stat Med 2003; 22: 353-362.
45. Spiegelhalter DJ, Thomas A, Best N. WinBUGS version 1.2. MRC Biostatistics Unit: Cambridge, UK, 1999.